News und Analysen

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

AMN Healthcare donated $1.1 million to a wide variety of charitable organizations in 2021 through a program to reward AMN healthcare professionals for their outstanding service while supporting

Humana Inc. (NYSE: HUM) announced today that it has been named the #1 Military Friendly Employer in the nation in the large company category by Viqtory Media for the second year in a row.

“Humana

Charles River Laboratories International, Inc. (NYSE:CRL) today announced that Birgit Girshick has been promoted to the position of Chief Operating Officer, effective immediately.

In her most

The Chula Vista Planning Commission today approved a new inpatient behavioral health hospital in the Eastlake community of Chula Vista. The Eastlake behavioral health hospital will be operated by a

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare

Humana Inc. (NYSE: HUM) announced today that its Veteran population is the latest addition to its Bold Goal communities. The Bold Goal is Humana’s ambitious population health strategy to improve

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

• 
  Barclays Gene Editing & Gene
  

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the third quarter and nine months ended

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed’s existing share repurchase program

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 36-cents per share on the Company’s capital stock, payable on December 6, 2021

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the

AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2021 financial

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Credit Suisse 30^th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at approximately

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights.

“We are delighted to share

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today